Leerink Swann's investment bankers craft solutions to client needs using the following disciplines.
Leerink Swann helps private companies raise capital in private markets, using institutional and individual debt and equity sources.
Our deep relationships and intimate understanding of the healthcare investment landscape are crucial to private placements. This knowledge enables our bankers to access the right investors for our clients in a pragmatic and efficient manner.
Leerink Swann underwrites public offerings, including Initial Public Offerings and Follow-on Offerings.
Capitalizing on our relationships with healthcare investors, Leerink Swann promotes the offering through our institutional and retail sales forces, targets key investors and provides post-transaction support to help position clients for favorable outcomes. We have a rich history of successfully launching and completing Initial Public Offerings and Follow-On financings. Our singular focus on healthcare and the depth of our platform lead to a higher level of dialogue with analysts and portfolio managers. This enables us to provide exceptional service and execution, which ultimately drives value for our clients. Leerink Swann employs more dedicated healthcare salespeople, sales traders, and position traders than many other firms on the Street.
Our proprietary access to MEDACorp is a key differentiator during the deal-making process, as we are able to leverage these key insights to better inform decisions within the capital markets arena.
Leerink Swann structures and places PIPEs and RDOs that allow public companies to raise capital without the time or expense of public offerings. Our combination of focused relationships and domain expertise helps clients obtain institutional-investor support on terms often favorable to current shareholders.
Leerink Swann assists clients in the selling and buying of companies, mergers, joint ventures and divestitures. Our M&A guidance is based on our integrated expertise in financial services and healthcare. By leveraging the knowledge of our banking team, MEDACorp, and our Strategic Advisors Group, Leerink Swann provides enhanced M&A capabilities designed to optimize shareholder value.
Leerink Swann's banking team is composed of professionals who have combined to execute over 200 M&A transactions in their careers valued at more than $400 billion. In addition, our exclusive access to MEDACorp equips our banking team with an enhanced resource for conducting product due diligence, positioning of assets and evaluation of partner assets. Finally, as a healthcare investment bank with a Strategic Advisors Group that provides consulting services to big pharma and emerging-growth companies, our combined knowledge base yields valuable insights to the planning, execution and post-transaction processes.